AMOTL1 Promotes Breast Cancer Progression and Is Antagonized by Merlin

Neoplasia (United States)

Volumn 18, Issue 1, 2016, Pages 10-24

  Couderc, Christophe ^a,b   Boin, Alizée ^a,b   Fuhrmann, Laetitia ^a,b,c   Vincent Salomon, Anne ^a,c,j   Mandati, Vinay ^a,b   Kieffer, Yann ^a,d   Mechta Grigoriou, Fatima ^a,d   Del Maestro, Laurence ^a,b   Chavrier, Philippe ^a,b   Vallerand, David ^a,e   Brito, Isabelle ^a,f,g   Dubois, Thierry ^a,h   De Koning, Leanne ^a,i   Bouvard, Daniel ^k,l   Louvard, Daniel ^a,b   Gautreau, Alexis ^m   Lallemand, Dominique ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c Department of Biopathology ^*  (France)

^d INSERM   (France)

^e Laboratoire d'Investigation Préclinique   (France)

^f INSERM U900   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h AAREC Filia Research   (France)

ⁱ RPPA Platform   (France)

^j INSTITUT CURIE   (France)

^k INSTITUT ALBERT BONNIOT   (France)

^l UNIV GRENOBLE ALPES   (France)

^m LABORATOIRE DE BIOCHIMIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOMOTIN LIKE PROTEIN 1; MERLIN; ONCOPROTEIN; PROTEASOME; PROTEIN TYROSINE KINASE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; AMOTL1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PROTEIN BINDING; TRANSCRIPTION FACTOR; YY1AP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL MOTION; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MEMBRANE PROTEINS; MICE; NEUROFIBROMIN 2; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEOLYSIS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSCRIPTION FACTORS;

EID: 84963935837     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.11.010     Document Type: Article

References (39)

1. Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG, Holmgren L Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 2002, 298:69-77.
2. Troyanovsky B, Levchenko T, Månsson G, Matvijenko O, Holmgren L Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001, 152:1247-1254.
3. Bratt A, Birot O, Sinha I, Veitonmäki N, Aase K, Ernkvist M, Holmgren L Angiomotin regulates endothelial cell-cell junctions and cell motility. J Biol Chem 2005, 280:34859-34869.
4. Zheng Y, Vertuani S, Nyström S, Audebert S, Meijer I, Tegnebratt T, Borg JP, Uhlén P, Majumdar A, Holmgren L Angiomotin-like protein 1 controls endothelial polarity and junction stability during sprouting angiogenesis. Circ Res 2009, 105:260-270.
5. Gagné V, Moreau J, Plourde M, Lapointe M, Lord M, Gagnon E, Fernandes MJ Human angiomotin-like 1 associates with an angiomotin protein complex through its coiled-coil domain and induces the remodeling of the actin cytoskeleton. Cell Motil Cytoskeleton 2009, 66:754-768.
6. Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC, Liu Q, Shimono A, Sudol M, Holmgren L, et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal 2013, 6:ra77. [http://dx.doi.org/10.1126/scisignal.2004060].
7. Zhao B, Li L, Lu Q, Wang LH, Liu C-Y, Lei Q, Guan KL Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011, 25:51-63.
8. Dai X, She P, Chi F, Feng Y, Liu H, Jin D, Zhao Y, Guo X, Jiang D, Guan KL, et al. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem 2013, 288:34041-34051.
9. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, Persson NL, Shimono A, Speicher DW, Marmorstein R, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011, 19:527-540.
10. Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 2006, 6:6-16.
11. Yang J, Liu P, Tian M, Li Y, Chen W, Li X Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma. Int J Oncol 2013, 42:2078-2086.
12. Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, Sun Y, Hudmon A, Wells CD Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci U S A 2013, 110:17368-17373.
13. Wang C, An J, Zhang P, Xu C, Gao K, Wu D, Wang D, Yu H, Liu JO, Yu L The Nedd4-like ubiquitin E3 ligases target angiomotin/p130 to ubiquitin-dependent degradation. Biochem J 2012, 444:279-289.
14. Oka T, Schmitt AP, Sudol M Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene 2012, 31:128-134.
15. Wells CD, Fawcett JP, Traweger A, Yamanaka Y, Goudreault M, Elder K, Kulkarni S, Gish G, Virag C, Lim C, et al. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 2006, 125:535-548.
16. Ranahan WP, Han Z, Smith-Kinnaman W, Nabinger SC, Heller B, Herbert B-S, Chan R, Wells CD The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases. Cancer Res 2011, 71:2203-2211.
17. Wang W, Huang J, Chen J Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem 2011, 286:4364-4370.
18. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011, 286:7018-7026.
19. Wang Y, Li Z, Xu P, Huang L, Tong J, Huang H, Meng A Angiomotin-like2 gene (amotl2) is required for migration and proliferation of endothelial cells during angiogenesis. J Biol Chem 2011, 286:41095-41104.
20. Ernkvist M, Luna Persson N, Audebert S, Lecine P, Sinha I, Liu M, Schlueter M, Horowitz A, Aase K, Weide T, et al. The Amot/Patj/Syx signaling complex spatially controls RhoA GTPase activity in migrating endothelial cells. Blood 2009, 113:244-253.
21. Chen Y, Gutmann DH, Haipek CA, Martinsen BJ, Bronner-Fraser M, Krull CE Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration. Dev Dyn 2004, 229:541-554.
22. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006, 25:5960-5968.
23. Hartmann M, Parra LM, Ruschel A, Schubert S, Li Y, Morrison H, Herrlich A, Herrlich P Tumor suppressor NF2 blocks cellular migration by inhibiting ectodomain cleavage of CD44. Mol Cancer Res 2015, 13(5):879-890.
24. Das T, Safferling K, Rausch S, Grabe N, Boehm H, Spatz JP A molecular mechanotransduction pathway regulates collective migration of epithelial cells. Nat Cell Biol 2015, 17:276-287.
25. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013, 154:1342-1355.
26. Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, Tucker JA, Samant RS, Shevde LA Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem 2011, 286:40376-40385.
27. Lau Y-KI, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q Merlin is a potent inhibitor of glioma growth. Cancer Res 2008, 68:5733-5742.
28. Murray LB, YuQ Lau Y-KI Merlin is a negative regulator of human melanoma growth. PLoS One 2012, 7:e43295.
29. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJ, Testa JR High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995, 92:10854-10858.
30. Moroishi T, Hansen CG, Guan KL The emerging roles of Yap and Taz in cancer. Nat Rev Cancer 2015, 15(2):73-79.
31. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Demidenko E, Korc M, Shi W, Preis M, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 2011, 71:873-883.
32. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008, 14:370-378.
33. Hannemann J, Velds A, Halfwerk JBG, Kreike B, Peterse JL, van de Vijver MJ Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006, 8:R61.
34. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, Reyal F, Radvanyi F, Salmon R, Thiery JP, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008, 14:1956-1965.
35. Yu K, Lee CH, Tan PH, Tan P Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004, 10:5508-5517.
36. Prat A, Cheang MCU, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013, 31:203-209.
37. Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E, Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, et al. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One 2013, 8:e63712.
38. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15.
39. Li Q, Birkbak NJ, Gyorffy B, Szallasi Z, Eklund AC Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 2011, 12:474.